These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

95 related articles for article (PubMed ID: 11707751)

  • 21. The Vioxx debacle revisited.
    Abeles M; Abeles AM
    Am J Med; 2005 Sep; 118(9):1057-8. PubMed ID: 16164907
    [No Abstract]   [Full Text] [Related]  

  • 22. COX-2 inhibitors: new drugs for the management of pain and inflammation.
    Hutchins V; Hutchins B
    Dent Today; 2001 Feb; 20(2):56-61. PubMed ID: 12524847
    [No Abstract]   [Full Text] [Related]  

  • 23. Matters of the heart: assessing the cardiovascular safety of new drugs.
    Konstam MA
    Am Heart J; 2003 Oct; 146(4):561-2. PubMed ID: 14564304
    [No Abstract]   [Full Text] [Related]  

  • 24. [Analgesic in osteoporosis. Why so conservative with dosage?].
    Pfeifer M
    MMW Fortschr Med; 2002 Sep; 144(35-36):9. PubMed ID: 12380349
    [No Abstract]   [Full Text] [Related]  

  • 25. Cutaneous vasculitis induced by cyclo-oxygenase-2 selective inhibitors.
    Drago F; Brusati C; Desirello G; Cacciapuoti M; Rebora A
    J Am Acad Dermatol; 2004 Dec; 51(6):1029-30. PubMed ID: 15583611
    [No Abstract]   [Full Text] [Related]  

  • 26. [Vision impairment by COX-2 inhibitor and the sequelae of voluntary Vioxx recall].
    Meyer CH
    Klin Monbl Augenheilkd; 2005 Jan; 222(1):62-3. PubMed ID: 15678404
    [No Abstract]   [Full Text] [Related]  

  • 27. Clinical trials. Nail-biting time for trials of COX-2 drugs.
    Couzin J
    Science; 2004 Dec; 306(5702):1673-5. PubMed ID: 15576585
    [No Abstract]   [Full Text] [Related]  

  • 28. The coxibs, selective inhibitors of cyclooxygenase-2.
    Killen JP
    N Engl J Med; 2001 Dec; 345(23):1708; author reply 1709. PubMed ID: 11759656
    [No Abstract]   [Full Text] [Related]  

  • 29. Relationship between selective cyclooxygenase-2 inhibitors and acute myocardial infarction in older adults.
    Solomon DH; Schneeweiss S; Glynn RJ; Kiyota Y; Levin R; Mogun H; Avorn J
    Circulation; 2004 May; 109(17):2068-73. PubMed ID: 15096449
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Cardiovascular effects of selective cyclooxygenase-2 inhibitors.
    Krum H; Liew D; Aw J; Haas S
    Expert Rev Cardiovasc Ther; 2004 Mar; 2(2):265-70. PubMed ID: 15151474
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Rofecoxib, Merck, and the FDA.
    Wolfe MM
    N Engl J Med; 2004 Dec; 351(27):2875-8; author reply 2875-8. PubMed ID: 15625749
    [No Abstract]   [Full Text] [Related]  

  • 32. [Cyclooxygenase-2 inhibitors and the ethics of research].
    Gherardi CR
    Medicina (B Aires); 2005; 65(5):476. PubMed ID: 16296649
    [No Abstract]   [Full Text] [Related]  

  • 33. [A critical evaluation of side effect data on COX-2 inhibitors].
    Pomp E
    Tidsskr Nor Laegeforen; 2002 Feb; 122(5):476-80. PubMed ID: 11961974
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Treatment of rheumatoid arthritis and osteoarthritis with COX-2-selective inhibitors: a managed care perspective.
    Hochberg MC
    Am J Manag Care; 2002 Nov; 8(17 Suppl):S502-17. PubMed ID: 12458820
    [TBL] [Abstract][Full Text] [Related]  

  • 35. GI events leading to death in association with celecoxib and rofecoxib.
    Weaver J; Bonnel RA; Karwoski CB; Brinker AD; Beitz J
    Am J Gastroenterol; 2001 Dec; 96(12):3449-50. PubMed ID: 11774975
    [No Abstract]   [Full Text] [Related]  

  • 36. Does the pro-hypertensive effect of cyclooxygenase-2 inhibitors account for the increased risk in cardiovascular disease?
    Messerli FH; Sichrovsky T
    Am J Cardiol; 2005 Sep; 96(6):872-3. PubMed ID: 16169380
    [No Abstract]   [Full Text] [Related]  

  • 37. Drug safety. FDA panel urges caution on many anti-inflammatory drugs.
    Couzin J
    Science; 2005 Feb; 307(5713):1183-5. PubMed ID: 15731414
    [No Abstract]   [Full Text] [Related]  

  • 38. [Specific inhibitors of cyclooxygenase type 2] ].
    Tomasová-Studýnková J
    Vnitr Lek; 2002 May; 48(5):403-8. PubMed ID: 12061207
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Tubulointerstitial nephritis associated with treatment with selective Cox-2 inhibitors, celecoxib and rofecoxib].
    Ortiz M; Mon C; Fernández MJ; Sánchez R; Mampaso F; Alvarez Ude F
    Nefrologia; 2005; 25(1):39-43. PubMed ID: 15789535
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Selective cyclooxygenase-2 inhibitors and the digestive tract].
    Chaabouni H; Amouri A; Cheikh I; Kchaou M; Ouerghi H; Ben Mami N; Ben Ammar A
    Tunis Med; 2002 Aug; 80(8):427-33. PubMed ID: 12703120
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.